10-K Decoder · All companies

Janux Therapeutics, Inc.

JANX · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026

Open the dashboardInfographicSummary

FY2025 key figures

$FY2025FY2024Change
Revenue$10.0M$10.6M−5.6%
Operating income−$158M−$98.8M−59.5%
Net income−$114M−$69.0M−64.7%

Latest quarter: Q3 2026

Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026

$Q3 2026Year earlierChange
Revenue$9.30M$10.0M−7.0%
Operating income−$31.3M−$35.3M+11.3%
Net income−$21.6M−$24.3M+11.1%

Q3 2026 dashboardQ3 2026 infographic

Questions

What was Janux Therapeutics's revenue in FY2025?
$10.0M in FY2025 (Fiscal year ended Dec 31, 2025), −5.6% vs $10.6M a year earlier, per its 10-K filed Feb 2026.
Was Janux Therapeutics profitable in FY2025?
No: net income was −$114M and operating income −$158M in FY2025.
What was Janux Therapeutics's revenue in Q3 2026?
$9.30M (−7.0% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.